IGF1 and metabolic dysfunction-associated steatohepatitis: In conclusion, we demonstrated that IGF-I induces senescence of HSCs, inactivates these cells and limits fibrosis in a p53-dependent manner and a potential therapeutic application of IGF-I for the treatment of NASH and cirrhosis.